Technical Analysis for INAB - IN8bio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.14 | 0.88% | 0.01 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.88% | |
| Crossed Above 200 DMA | Bullish | 0.88% | |
| Crossed Above 50 DMA | Bullish | 0.88% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | 0.88% | |
| Pocket Pivot | Bullish Swing Setup | 0.88% | |
| Bollinger Band Squeeze | Range Contraction | 0.88% | |
| Wide Range Bar | Range Expansion | 0.88% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.88% | |
| Outside Day | Range Expansion | 0.88% | |
| Above Upper BB | Strength | 0.88% |
| Alert | Time |
|---|---|
| 50 DMA Support | 12 minutes ago |
| Down 2 % | 12 minutes ago |
| Down 1% | 12 minutes ago |
| Up 1% | 12 minutes ago |
| Fell Below Upper Bollinger Band | 12 minutes ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/10/2024
IN8bio, Inc. Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Treatment Of Cancer Stem Cell Transplantation Solid Tumor Cancers Acute Leukemia Regenerative Medicine Advanced Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.48 |
| 52 Week Low | 0.65 |
| Average Volume | 376,477 |
| 200-Day Moving Average | 1.13 |
| 50-Day Moving Average | 1.11 |
| 20-Day Moving Average | 1.03 |
| 10-Day Moving Average | 1.02 |
| Average True Range | 0.07 |
| RSI (14) | 61.24 |
| ADX | 16.36 |
| +DI | 20.36 |
| -DI | 11.44 |
| Chandelier Exit (Long, 3 ATRs) | 0.94 |
| Chandelier Exit (Short, 3 ATRs) | 1.16 |
| Upper Bollinger Bands | 1.09 |
| Lower Bollinger Band | 0.97 |
| Percent B (%b) | 1.35 |
| BandWidth | 11.67 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.03 |
| MACD Histogram | 0.0138 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.39 | ||||
| Resistance 3 (R3) | 1.37 | 1.26 | 1.34 | ||
| Resistance 2 (R2) | 1.26 | 1.20 | 1.27 | 1.33 | |
| Resistance 1 (R1) | 1.20 | 1.16 | 1.23 | 1.22 | 1.31 |
| Pivot Point | 1.09 | 1.09 | 1.11 | 1.10 | 1.09 |
| Support 1 (S1) | 1.03 | 1.03 | 1.06 | 1.05 | 0.95 |
| Support 2 (S2) | 0.92 | 0.99 | 0.93 | 0.93 | |
| Support 3 (S3) | 0.86 | 0.92 | 0.92 | ||
| Support 4 (S4) | 0.88 |
